Ricciardi S - Search Results

1

Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.

Landi L, Tiseo M, Chiari R, Ricciardi S, Rossi E, Galetta D, Novello S, Milella M, D'Incecco A, Minuti G, Tibaldi C, Salvini J, Facchinetti F, Haspinger ER, Cortinovis D, Santo A, Banna G, Catino A, GiajLevra M, Crinò L, de Marinis F, Cappuzzo F. Landi L, et al. Among authors: ricciardi s. Clin Lung Cancer. 2014 Nov;15(6):411-417.e4. doi: 10.1016/j.cllc.2014.07.002. Epub 2014 Aug 16. Clin Lung Cancer. 2014. PMID: 25242668 Free article.

2

Toxicity of targeted therapy in non-small-cell lung cancer management.

Ricciardi S, Tomao S, de Marinis F. Ricciardi S, et al. Clin Lung Cancer. 2009 Jan;10(1):28-35. doi: 10.3816/CLC.2009.n.004. Clin Lung Cancer. 2009. PMID: 19289369 Review.

3

Multimodality management of non-small cell lung cancer patients with brain metastases.

Ricciardi S, de Marinis F. Ricciardi S, et al. Curr Opin Oncol. 2010 Mar;22(2):86-93. doi: 10.1097/CCO.0b013e3283350106. Curr Opin Oncol. 2010. PMID: 20009927 Review.

4

Treatment of bone metastases in lung cancer: the actual role of zoledronic acid.

Ricciardi S, de Marinis F. Ricciardi S, et al. Rev Recent Clin Trials. 2009 Sep;4(3):205-11. doi: 10.2174/157488709789957718. Rev Recent Clin Trials. 2009. PMID: 20028333 Review.

5

New agents in advanced non-small-cell lung cancer treatment.

Ricciardi S, de Marinis F. Ricciardi S, et al. Oncology. 2009;77 Suppl 1:103-12. doi: 10.1159/000258502. Epub 2010 Feb 2. Oncology. 2009. PMID: 20130438 Review.

6

Treatment of advanced non-small-cell lung cancer: Italian Association of Thoracic Oncology (AIOT) clinical practice guidelines.

de Marinis F, Rossi A, Di Maio M, Ricciardi S, Gridelli C; Italian Association of Thoracic Oncology. de Marinis F, et al. Among authors: ricciardi s. Lung Cancer. 2011 Jul;73(1):1-10. doi: 10.1016/j.lungcan.2011.02.022. Epub 2011 Mar 25. Lung Cancer. 2011. PMID: 21440325

7

Second-line treatment options in advanced non-small cell lung cancer.

de Marinis F, Ricciardi S. de Marinis F, et al. Among authors: ricciardi s. Eur J Cancer. 2011 Sep;47 Suppl 3:S258-71. doi: 10.1016/S0959-8049(11)70172-1. Eur J Cancer. 2011. PMID: 21943983 Review. No abstract available.

8

Oral tyrosine kinase inhibitors in the first-line treatment of advanced non-small cell lung cancer.

Gori B, Ricciardi S, del Signore E, Fulvi A, de Marinis F. Gori B, et al. Among authors: ricciardi s. Expert Opin Ther Targets. 2012 Apr;16 Suppl 2:S55-60. doi: 10.1517/14728222.2011.652617. Epub 2012 Mar 23. Expert Opin Ther Targets. 2012. PMID: 22443258 Review.

9

Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer.

Ricciardi S, Tomao S, de Marinis F. Ricciardi S, et al. Lung Cancer (Auckl). 2010 Dec 20;2:1-9. doi: 10.2147/LCTT.S10167. eCollection 2011. Lung Cancer (Auckl). 2010. PMID: 28210114 Free PMC article. Review.

10

Final results of the SENECA (SEcond line NintEdanib in non-small cell lung CAncer) trial.

Capelletto E, Migliorino MR, Morabito A, Chiari R, Grossi F, Tiseo M, Costanzo FD, Delmonte A, Romano G, Galetta D, Scotti V, Gregorc V, Pisconti S, Ceresoli GL, Del Conte A, Ciuffreda L, Colantonio I, Bria E, Ricciardi S, Manzo A, Metro G, Morelli AM, Critelli R, Pacchiana MV, Stura I, Migliaretti G, Novello S. Capelletto E, et al. Among authors: ricciardi s. Lung Cancer. 2019 Aug;134:210-217. doi: 10.1016/j.lungcan.2019.06.028. Epub 2019 Jun 27. Lung Cancer. 2019. PMID: 31319983 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

589 results

Search Page

Filters